Perspectives on inducing efficient immune control of HIV-1 replication - A new goal for HIV therapeutics?

AIDS

Volumn 15, Issue SUPPL. 2, 2001, Pages

  Bucy, R P ^a   Kilby, J M ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cytotoxic T lymphocytes; HAART; HIV 1; Structured therapy interruption

Indexed keywords

ANTIRETROVIRUS AGENT; LYMPHOCYTE ANTIBODY; VIRUS ANTIGEN;

CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CLONAL ANERGY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; LONG TERM CARE; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; IMMUNOTHERAPY; MACACA MULATTA; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

EID: 0035090187     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102002-00007     Document Type: Conference Paper

References (106)

1. Viral dynamics in human immunodeficiency virus type 1 infection
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
3. Prognosis in HIV infection predicted by the quantity of virus in plasma
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. HIV-protease inhibitors
8. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
9. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
10. Decay characteristics of HIV-1-infected compartments during combination therapy
11. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
12. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
13. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
14. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
15. Toward HIV eradication or remission: The tasks ahead
16. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy
17. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
18. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
19. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
20. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
21. The immunopathogenesis of human immunodeficiency virus infection
22. Host factors and the pathogenesis of HIV-induced disease
23. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1
24. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies
25. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
26. Reduction of HIV concentration during acute infection: Independence from a specific immune response
27. + T cell responses associated with control of viremia
28. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
29. + T cell homeostasis and function in advanced HIV disease
30. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
31. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
32. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
33. AIDS virus-specific cytotoxic T lymphocytes in lung disorders
34. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
35. A novel method for detection and ex vivo expansion of HIV type 1-specifc cytolytic T lymphocytes
36. Acute human immunodeficiency virus Type 1 infection
37. Cytotoxic-T-cell responses, viral load, and disease progression in early human immundeficiency virus 1 infection
38. + T lymphocytes with changes in viral load
39. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-alpha), and TNF-beta when they encounter their target antigens
40. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-producing cells
41. + T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure
42. HIV-1-specific cytotoxic T lymphocyte response in healthy, long-term nonprogressing seropositive persons
43. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression
44. + T cells in HIV-infected progressors and long-term nonprogressors
45. Phenotypic analysis of antigen-specific T lymphocytes
46. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
47. Longitudinal phenotypic analysis of human immunodeficiency virus type 1 -specific cytotoxic T lymphocytes: Correlation with disease progression
48. + T cells proliferating in response to influenza A antigen
49. Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in Simian/Human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer
50. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
51. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
52. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects
53. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
54. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
55. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia
56. Broad, intense antihuman immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy
57. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
58. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo
59. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection
60. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
61. Dynamics of HIV variants and specific cytotoxic T-cell recognition in nonprogressors and progressors
62. T cell responses and viral escape
63. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
64. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
65. Containment of breakthrough HIV plasma viremia in the absence of antiretorviral drug therapy is associated with a broad and vigorous HIV specific cytotoxic T lymphocyte (CTL) response
66. HIV-1-Specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
67. Immune control of HIV-1 following early treatment of acute infection
68. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
69. + cell count and rate of progression to AIDS following acute HIV-1 infection. Multicenter AIDS Cohort Study
70. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
71. + lymphocyte appears in lymph nodes of rhesus monkeys early after infection with simian immunodeficiency virus
72. The repertoire of cytotoxic T lymphocytes in the recognition of mutant simian immunodeficiency virus variants
73. The T cell receptor gene usage by simian immunodeficiency virus gag-specific cytotoxic T lymphocytes in rhesus monkeys
74. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
75. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
76. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
77. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
78. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine
79. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes
80. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
81. + T cells in controlling SIVmac infection using a CD8 cell depleting mAb in vivo in Rhesus monkeys
82. Population dynamics of immune responses to persistent viruses
83. Immune clearance of HIV-1 replication active cells: A model of two patterns of steady state HIV infection
84. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
85. Evaluation of instinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy
86. + T helper cell function in vivo: Differential requirement for induction of antiviral cytotoxic T-cell and antibody responses
87. + cytotoxic T-cell responses during chronic viral infection
88. Immunological memory and protective immunity: Understanding their relation
89. Quantitative analysis of the acute and long-term CD4(+) T-cell response to a persistent gamma-herpesvirus
90. + T cell memory
91. Preserving HIV-1 specific T-cell help: Will it prevent progression?
92. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis
93. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120
94. gp120 is present on the plasma membrane of apoptotic CD4 cells prepared from lymph nodes of HIV-1-infected individuals: An immunoelectron microscopic study
95. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
96. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine
97. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells
98. + T cell proliferation and production of IFN-gamma in rsponse to p24 atigen in HIV-infected individuals: Potential contribution of anergy to HIV-specific unresponsiveness
99. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor
100. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
101. Immune control of HIV after suspension of therapy
102. Intermittent drug therapy increases the time to HIV rebound in humans and induces the control of SIV after treatment interruption in monkeys
103. Effects of HAART corn pared to HAART plus an inactivated HIV immunogen on lymphocyte proliferative responses (LPR) to HIV antigens
104. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
105. Cessation of HAART plus daily low-dose interleukin-2 to promote immunity to HIV
106. SITT: A prospective trial of strategic treatment interruptions